Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Apr 14, 2020 3:31am
137 Views
Post# 30906188

RE:TLD-1433 is being used in the current PH2 trial

RE:TLD-1433 is being used in the current PH2 trialSkyhawk - do you seriously fail to appreciate that all that 'gibberish' wasn`t about TLD-1433 at all but about something far,far better that they had at the time of the NMIBC Trial but didn`t use then and that they still have now but have neither used nor updated shareholders on?

It may not matter to you that the share price is at 18 cents or that the fundraising was at 30 cents but this represented significant dilution that further cost the Company in terms of lost capital that could otherwise already be deployed in funding Trials of this superior treatment in indications where TLD-1433 alone would be useless?

It is Management`s responsibility to maintain an orderly market in the shares for these and many other reasons.This could have been and could still be done with responsible reporting of the Company`s true prospects and potential.
 
Bullboard Posts